IMPACT OF ROPEGINTERFERON AND RUXOLITINIB ON JAK2 VARIANT ALLELE FREQUENCY IN POLYCYTHEMIA VERA: A SINGLE-CENTER REAL-LIFE STUDY (SIE 2026) - Oct 6, 2026 - Abstract #SP123; "Ninety-two patients (56 male, 36 females; median age 58 years) were included: 19 treated with Hydroxyurea (HU) (21%), 27 with Ropeginterferon (Ropeg) (29%), 40 with Ruxolitinib (Ruxo) (43%), 3 with Ruxo+Ropeg (3%) (Table 1). Therapy influences JAK2 VAF and hematolog- ic response in PV. Monitoring and modulating JAK2 VAF may help achieve durable remissions, improving prognosis and quality of life."
Clinical • Myelofibrosis • Polycythemia Vera • JAK2 • KIT
|
|
G. Berutto1; A. Cavallaro2; B. Patarnello1; M. Scaldaferri3; P. Francia Di Celle4; L. Riera4; L. Celona1; E. Boscaro1; C. Frairia1; M. Cerrano1; E. Santambrogio1; G. Lanzarone2; E. Audisio1; S. D'Ardia1; G. Benevolo2; E. Beggiato2; R. Freilone1; V. Giai1
|